hydralazine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A series of 8 patients with chronic myeloid leukemia (CML) refractory to imatinib mesylate with no access to second-generation tyrosine kinase inhibitors were treated with hydralazine and valproate in a compassionate manner." | 1.38 | Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia. ( Candelaria, M; Cervera, E; Cortes, J; Dueñas-González, A; Gonzalez-Fierro, A; Gordillo-Bastidas, D; Labardini, J; López-Navarro, O; Taja-Chayeb, L, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cervera, E | 1 |
| Candelaria, M | 1 |
| López-Navarro, O | 1 |
| Labardini, J | 1 |
| Gonzalez-Fierro, A | 1 |
| Taja-Chayeb, L | 1 |
| Cortes, J | 1 |
| Gordillo-Bastidas, D | 1 |
| Dueñas-González, A | 1 |
1 other study available for hydralazine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Fo | 2012 |